Ana Laus to Melanoma
This is a "connection" page, showing publications Ana Laus has written about Melanoma.
Connection Strength
0.560
-
Sorroche BP, de Jesus Teixeira R, de Souza VG, Tosi IC, Tostes K, Laus AC, Santana IVV, de Lima Vazquez V, Arantes LMRB. CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival. J Mol Med (Berl). 2025 Jun; 103(6):725-737.
Score: 0.181
-
Marczynski GT, Laus AC, Dos Reis MB, Reis RM, Vazquez VL. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Sci Rep. 2020 10 29; 10(1):18682.
Score: 0.133
-
de Carvalho CEB, Capuzzo R, Crovador C, Teixeira RJ, Laus AC, Carvalho AL, Vazquez VL. Near Infrared (NIR) Fluorescence is Not a Substitute for Lymphoscintigraphy and Gamma Probe for Melanoma Sentinel Node Detection: Results from a Prospective Trial. Ann Surg Oncol. 2020 Aug; 27(8):2906-2912.
Score: 0.128
-
Vicente ALSA, Bianchini RA, Laus AC, Macedo G, Reis RM, Vazquez VL. Comparison of protocols for removal of melanin from genomic DNA to optimize PCR amplification of DNA purified from highly pigmented lesions. Histol Histopathol. 2019 Sep; 34(9):1089-1096.
Score: 0.119